Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

| More on:
A young woman lifts her red glasses with one hand as she takes a closer look at news about interest rates rising and one expert's surprising recommendation as to which ASX shares to buy

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week.

Three ASX shares that brokers have named as buys this week are listed below. Here's why their analysts are feeling bullish on them right now:

Gentrack Group Ltd (ASX: GTK)

According to a note out of Bell Potter, its analysts have retained their buy rating on this utilities software company's shares with a trimmed price target of $13.20. This follows the release of a half year result this week that was below expectations. Bell Potter notes that project revenues within utilities dragged slightly against a strong prior period and the phasing of contract wins. Nevertheless, it remains positive on the future and is bullish on Gentrack's ability to maintain customer win momentum. It expects this to support high NRR revenues, which will flow onto ARR. The Gentrack share price is trading at $10.57 on Wednesday afternoon.

ResMed Inc. (ASX: RMD)

A note out of Goldman Sachs reveals that its analysts have retained their conviction buy rating and $49.30 price target on this sleep disorder treatment company's shares. This follows news that Apnimed has had success with its phase 3 trial of a sleep apnoea pill. Goldman Sachs isn't concerned and feels that the share price weakness caused by the news has been an overreaction. It believes that Apnimed's AD109's pill is unlikely to displace CPAP as first line therapy in treating OSA. Particularly given that its initial target opportunity are patients who have refused or have failed CPAP. In light of this, Goldman Sachs remains as bullish as ever on ResMed and its long term zoutlook. The ResMed share price is fetching $38.80 at the time of writing.

TechnologyOne Ltd (ASX: TNE)

Analysts at UBS have retained their buy rating on this enterprise software company's shares with an improved price target of $42.20. According to the note, the broker was impressed with TechnologyOne's half year results. It highlights that annual recurring revenue grew strongly and was in line with its expectations. Whereas its profits were comfortably ahead of its estimates for the half. Combined with its strong net revenue retention rate and ultra low churn levels, it believes the result supports its bullish view on the long term growth outlook of the company. The Technology One share price is trading at $38.46 this afternoon.

Motley Fool contributor James Mickleboro has positions in ResMed and Technology One. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Gentrack Group, Goldman Sachs Group, ResMed, and Technology One. The Motley Fool Australia has positions in and has recommended Gentrack Group and ResMed. The Motley Fool Australia has recommended Technology One. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Smiling man sits in front of a graph on computer while using his mobile phone.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

White declining arrow on a blue graph with an animated man representing a falling share price.
Materials Shares

Experts call time on these rip-snorting ASX 200 mining shares

These 2 ASX 200 mining stocks have risen by 160% and 230%, respectively, over the past 12 months.

Read more »

Two people comparing and analysing material.
Broker Notes

Buy, hold, sell: Netwealth, Santos, and South32 shares

Morgans has given its verdict on these shares following updates.

Read more »

Business man at desk looking out window with his arms behind his head at a view of the city and stock trends overlay.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Three smiling corporate people examine a model of a new building complex.
Broker Notes

Broker says this ASX All Ords stock could rise 15%

Bell Potter thinks investors should be buying this growing company's shares.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Broker Notes

Why Lynas shares could crash 33%

Bell Potter believes this rare earths stock could lose a third of its value.

Read more »

Three girls compete in a race, running fast around an athletic track.
Broker Notes

Two ASX 200 stocks to buy after crashing 6-9% yesterday

Bell Potter is tipping an 18-40% resurgence for these stocks.

Read more »

A woman looks quizzical as she looks at a graph of the share market.
Broker Notes

Looking for double-digit returns? Check out RBC Capital Markets' picks ahead of reporting season

These shares could deliver strong upside.

Read more »